Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 4Lung Neoplasms 4Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Tertiary Lymphoid Structures 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Camurati-Engelmann Syndrome 1Brain Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Radiotherapy 2fresolimumab 1fludarabine 1bintrafusp alfa protein, human 1ascrinvacumab 1Losartan 1Cyclophosphamide 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Camurati-Engelmann Syndrome × bintrafusp alfa protein, human × Clear all
NCT04297748 2023-01-17

Bioimaging Study of 89Zr-M7824 in NSCLC

Olivia Newton-John Cancer Research Institute

Phase 1/2 Terminated
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡